Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes

Glucagon-like peptide 1 (GLP-1) receptor agonists and other incretin-based medications have transformed the treatment of type 2 diabetes, obesity, and related metabolic disorders. Semaglutide is approved by the FDA for long-term weight reduction, type 2 diabetes treatment, and reduction of cardiovascular events. Tirzepatide is a dual agonist of GLP-1 and other receptors, approved for diabetes treatment, weight reduction, and sleep apnea. Orforglipron is a new oral GLP-1 receptor agonist approved in the US for weight reduction in adults with overweight or obesity. Liraglutide is used for treating type 2 diabetes and obesity. Several new incretin-based medications are in advanced stages of clinical development or under review by regulatory agencies.